1. Cardiac myocyte-specific overexpression of human GTP cyclohydrolase I protects against acute cardiac allograft rejection
- Author
-
Ionova, Irina A., Vasquez-Vivar, Jeannette, Cooley, Brian C., Khanna, Ashwani K., Whitsett, Jennifer, Herrnreiter, Anja, Migrino, Raymond Q., Ge, Zhi-Dong, Regner, Kevin R., Channon, Keith M., Alp, Nicholas J., and Pieper, Galen M.
- Subjects
Graft rejection -- Physiological aspects ,Gene expression -- Physiological aspects ,Heart -- Transplantation ,Heart -- Physiological aspects ,Heart -- Patient outcomes ,Biological sciences - Abstract
GTP cyclohydrolase I (GTPCH) is the rate-limiting enzyme for tetrahydrobiopterin (BH4) synthesis. Decreases in GTPCH activity and expression have been shown in late stages of acute cardiac rejection, suggesting a deficit in BH4. We hypothesized that increasing intracellular levels of BH4 by cardiac myocyte-targeted overexpression of GTPCH would diminish acute cardiac allograft rejection. Transgenic mice overexpressing GTPCH in the heart were generated and crossed on C57BL6 background. Wild-type and transgenic mouse donor hearts were transplanted into BALB/c recipient mice. Left ventricular (LV) function, histological rejection, [BH.sub.4] levels, and inflammatory cytokine gene expression (mRNA) were examined. Expression of human GTPCH was documented by PCR, Western analysis, and function by a significant (P < 0.001) increase in cardiac BH4 levels. GTPCH transgene decreased histological rejection (46%; P < 0.003) and cardiac myocyte injury (eosin autofluorescence; 56%; P < 0.0001) independent of changes in inflammatory cytokine expression or nitric oxide content. GTPCH transgene decreased IL-2 (88%; P < 0.002), IL-1R2 (42%; P < 0.0001), and programmed cell death-1 (67%; P < 0.0001) expression, whereas it increased fins-like tyrosine kinase 3 (156%; P < 0.0001) and stromal-derived factor-1 (2; 190%; P < 0.0001) expression. There was no difference in ejection fraction or fractional shortening; however, LV mass was significantly increased (P < 0.05) only in wild-type grafts. The decreases in LV mass, cardiac injury, and histological rejection support a protective role of cardiac GTPCH overexpression and increased BIt4 synthesis in cardiac allografts. The mechanism of the decreased rejection appears related to decreased T cell proliferation and modulation of immune function by higher expression of genes involved in hematopoietic/stromal cell development and recruitment. tetrahydrobiopterin; rejection; stromal-derived factor 1; left ventricular mass; guanosine 5'-triphosphate cyclohydrolase doi: 10.1152/ajpheart.00203.2010.
- Published
- 2010